BrightHeart Receives the US FDA Approval for its AI Software Transforming Prenatal Fetal Heart Ultrasound Evaluations
Shots:
- BrightHeart has received the US FDA’s 510(k) clearance for its AI software revolutionizing fetal heart prenatal ultrasound evaluations
- The AI software enhances the detection of congenital heart defects (CHDs), the most common birth defect, enabling the early diagnosis of morphological abnormalities related to CHDs and intervention in resource-limited settings
- BrightHeart’s AI software analyzes fetal heart ultrasounds, aiding in prenatal CHD detection to improve pregnancy outcomes through early intervention and delivery planning
Ref: Businesswire | Image: BrightHeart
Related News:- Medable Collaborates with Google Cloud to Offer Digital Clinical Trials Technology on Google Cloud Marketplace
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
